CDx诊断公司将在2025年DDW会议上展示WATS3D的进展数据-动脉网

CDx Diagnostics to Present WATS3D Progression Data at DDW 2025

CISION 等信源发布 2025-05-02 23:00



可切换为仅中文







Highlights Continued Progress in Early Detection and the Progression of Esophageal Disease

强调了在食管疾病早期检测和进展方面取得的持续进展

SUFFERN, N.Y.

萨福恩，纽约州

，

May 2, 2025

2025年5月2日

/PRNewswire/ -- CDx Diagnostics announced today that new clinical data supporting the utility of the WATS

/PRNewswire/ -- CDx诊断公司今天宣布，支持WATS实用性的新临床数据已经发布

三维

test for Barrett's esophagus and dysplasia screening and surveillance has been selected for podium presentation at the 2025 Digestive Disease Week (DDW) in

用于巴雷特食管和异型增生筛查与监测的测试已被选为2025年消化疾病周（DDW）的讲台报告。

San Diego

圣地亚哥

, the premier conference for gastroenterology professionals. This podium presentation, along with additional data featured in a separate poster presentation, highlights WATS

，这是胃肠病学专业人士的顶级会议。这个讲台演讲以及另外一份海报展示中的更多数据突显了WATS的重要性。

3D'

s vital role in early detection, progression monitoring and risk assessment of patients at risk for Barrett's esophagus and esophageal cancer.

在巴雷特食管和食管癌高危患者的早期检测、进展监测和风险评估中起着至关重要的作用。

继续阅读

WATS

has consistently shown superior detection rates compared to conventional forceps biopsy (FB), the latter of which can miss up to 50% of cases. By sampling a broader area of mucosa and analyzing more cellular material using advanced 3D imaging, WATS

始终表现出比传统活检钳活检 (FB) 更高的检出率，后者可能漏诊多达 50% 的病例。通过采用更广泛的黏膜区域取样并利用先进的 3D 成像技术分析更多的细胞材料，WATS

三维

may help gastroenterologists detect Barrett's esophagus that might otherwise go undiagnosed.

可能有助于胃肠病学家检测出否则可能未被诊断的巴雷特食管。

New DDW 2025 data reveal WATS3D's enhanced capabilities for Barrett's detection, surveillance and risk assessment.

新的DDW 2025数据显示，WATS3D在巴雷特检测、监测和风险评估方面的能力得到了增强。

Post this

发布这个

Key Events at DDW 2025:

DDW 2025 关键事件：

Podium Presentation:

讲台演示：

'Progression Rates of Barrett's Esophagus and Dysplasia Detected by WATS3D Are Similar to Those Diagnosed by Forceps Biopsies'

'WATS3D检测到的巴雷特食管和异型增生的进展率与活检钳诊断的相似'

Poster Presentation:

海报展示：

'MUC2 Immunostaining Predicts Neoplastic Progression as Accurately as the Presence of Goblet Cells in Columnar-Lined Esophagus: A WATS3D Study of 3,553 Patients'

'MUC2免疫染色预测柱状食管上皮内瘤变进展的准确性与杯状细胞的存在相当：一项针对3,553名患者的WATS3D研究'

Nicholas J. Shaheen, MD will deliver the podium presentation, based on a collaborative study with Dr.

尼古拉斯·J. 沙欣医学博士将基于与博士的合作研究发表讲台演讲。

Michael Smith

迈克尔·史密斯

, Dr.

，博士。

Vivek Kaul

维韦克·考尔

, Mendel Singer Ph.D., and Dr.

，门德尔·辛格博士，以及博士。

Robert Odze

罗伯特·奥德兹

。

'The findings validate WATS3D's role in early detection,' said Dr. Shaheen. 'We're excited to share these results at DDW and discuss their impact on patient care.'

“研究结果证实了WATS3D在早期检测中的作用，”沙欣博士说。“我们很高兴在DDW上分享这些结果，并讨论它们对患者护理的影响。”

Robert D. Odze, MD noted that 'These studies advance our understanding of the biological significance of WATS3D detected lesions and their risk of progression to cancer in Barrett's esophagus.'

罗伯特·D. 奥德泽，医学博士指出：“这些研究增进了我们对WATS3D检测到的病灶的生物学意义及其在巴雷特食管中进展为癌症的风险的理解。”

The new data shared at DDW 2025 from

在DDW 2025上分享的新数据

May 3-6

5月3日至6日

offers important clinical insights into the evolving role of WATS

提供了对WATS不断演变的作用的重要临床见解

in Barrett's detection, surveillance and risk assessment. For more information, visit

在巴雷特检测、监测和风险评估中。欲了解更多信息，请访问

www.cdxdiagnostics.com

or contact us at

或联系我们 at

WATS3D@cdxdiagnostics.com

。

About CDx Diagnostics

关于CDx诊断

CDx Diagnostics' mission is to Empower Physicians with Innovative Technology to Prevent Esophageal Cancer,

CDx诊断公司的使命是通过创新技术赋予医生预防食管癌的能力，

One Patient

一位患者

at a Time. The company's proprietary diagnostic platform combines advanced computer imaging, artificial intelligence, molecular biology, and 3D cytopathology to detect precancerous changes earlier and more precisely than conventional methods. This pioneering solution has analyzed over 400,000 cases, empowering providers to identify those requiring early intervention, reduce time to treatment, and improve outcomes by detecting disease that might be missed by traditional forceps biopsies..

一次。该公司的专有诊断平台结合了先进的计算机成像、人工智能、分子生物学和三维细胞病理学，能够比传统方法更早、更精确地检测癌前变化。这一开创性解决方案已分析超过40万例病例，帮助医疗人员识别需要早期干预的患者，缩短治疗时间，并通过发现传统活检钳可能遗漏的疾病来改善治疗效果。

CONTACT:

联系人：

Logan Garrett

洛根·加勒特

lgarrett@bouvierkelly.com

l加勒特@布维尔凯利.com

423-519-9979

SOURCE CDx Diagnostics

源CDx诊断

WANT YOUR COMPANY'S NEWS

想要你公司的新闻